Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has ...
In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...
The guidelines, published Jan. 5 by the Health Resources and Services Administration, now recommend that average-risk women ...
Women with the BRCA gene mutations have a 60 to 80 percent chance of developing /topics/Breast_Cancer" class="cnnInlineTopic">breast cancer-- at least five times higher than the general population -- ...
Aranscia will provide software solutions to facilitate the delivery of results from InterVenn's flagship glycoproteomic liquid biopsy test.
InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback